4/19/2013

Neither canakinumab nor anakinra fared better than placebo in delaying beta-cell dysfunction in patients with new-onset type 1 diabetes, a study in The Lancet found. Researchers also noted a greater prevalence of adverse events in patients who took anakinra compared with those in the placebo group.

Related Summaries